Page 5 - 2017 V1 InsideOut

Select a defense against reinfection and provide post-exposure prophylaxis1
Indications
HepaGam B® [Hepatitis B Immune Globulin Intravenous (Human)] is an intravenous immune globulin indicated for the following:
• Prevention of Hepatitis B recurrence following liver transplant in HBsAg-positive liver transplant patients
• Post-exposure prophylaxis including:
- Acute exposure to HBsAg-positive blood, plasma, or serum (parenteral exposure, direct mucus membrane contact, oral ingestion, etc.),
- Perinatal exposure of infants born to HBsAg-positive mothers,
- Sexual exposure to HBsAg-positive persons, and
- Household exposure to persons with acute HBV infection
Selected Important Risk Information
Individuals known to have severe, potentially life-threatening reaction to human globulin preparations should not receive HepaGam B® or any other immune globulin (human). Individuals who are de cient in IgA may have the potential to develop IgA antibodies and have severe, potentially life-threatening allergic reactions.
Aptevo BioTherapeutics LLC, Berwyn, PA 19312
HepaGam B® [Hepatitis B Immune Globulin Intravenous (Human)] and any and all Aptevo BioTherapeutics LLC brand, product, service and feature names, logos, and slogans are trademarks or registered trademarks of Aptevo BioTherapeutics LLC in the United States and/or other countries.
© 2016 Aptevo BioTherapeutics LLC. All rights reserved. CM-HEPA-0010
Reference: 1. HepaGam B Prescribing Information, August 2016.
Please see Important Risk Information and full Prescribing Information at www.HepaGamB.com.